Xbrane Estimates Q1 2023 Resubmission For US Lucentis Biosimilar
FDA Pushed Back On Initial BLA Filing Earlier This Year
Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.
You may also be interested in...
Xbrane Eyes Positive Cash Flow In 2024 – But Out-Licensing Oncology Key
Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.
Stada And Xbrane Receive MHRA Nod For Ranibizumab
Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.
Regeneron ‘Shocked’ At Biogen Lucentis Biosimilar Sales
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.